NCT03767257: Phase 2: A Study of Colesevelam for Lenalidomide-Associated Diarrhea

• NCT03767257: Phase 2: A Study of Colesevelam for Lenalidomide-Associated Diarrhea

NCT03767257: Phase 2: A Study of Colesevelam for Lenalidomide-Associated Diarrhea

The purpose of this study is to test the safety of colesevelam and find out what effects, if any, colesevelam has on lenalidomide associated diarrhea in participants with multiple myeloma on lenalidomide maintenance.

Sponsor

Memorial Sloan Kettering Cancer Center

---

ClinicalTrials.gov Identifier: NCT03767257

Official Title: A Phase 2 Study of Colesevelam for Lenalidomide-Associated Diarrhea

First Posted : December 6, 2018

Click here to see details on ClinicalTrials.gov

---

Drug: Colesevelam Pill

---

Colesevelam

Colesevelam (Code C78056)

Colesevelam

COLESEVELAM

---

Locations

United States, New Jersey

United States, New York